Geron | GERN - Selling And Administration Expenses


Geron reported $35.42M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Amgen USD 1.72B 134M Jun/2026
Bio Techne USD 109.34M 4.35M Mar/2026
Cassava Sciences USD 3.89M 2.77M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
Exelixis USD 139.6M 16.58M Mar/2026
Genmab DKK 208M 60M Dec/2025
Geron USD 35.42M 6.24M Mar/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Novavax USD 25.53M 1.34M Dec/2025